Use and cardiovascular safety of transdermal and other granisetron preparations in cancer management.
5-HT3 antagonists have been available as oral and intravenous preparations for decades. The availability more recently of transdermal granisetron and the anticipated availability of a subcutaneous granisetron preparation have provided helpful alternatives to patients, and these preparations have been shown to have less potential to prolong QT than other drugs in the class.
School of Medicine, University of Utah, Salt Lake City, UT, USA.
Jay W
JW
Mason
Thomas E
TE
Moon
QT prolongation; chemotherapy-induced nausea; granisetron; vomiting